Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05764395 | Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors | terminated | Phase 2 | 7 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT01029873 | QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 22 | Altor BioScienceINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05665595 | A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) | terminated | Phase 3 | 1,594 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Sep 10, 2026 | clinicaltrials |
| NCT07076550 | A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma | terminated | Phase 1 | 5 | Alpha-9 Oncology USA Inc.INDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07193966 | NG2 and DLL3 CAR-T Cells Targeting Melanoma | terminated | Phase 1 / Phase 2 | 100 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05308901 | Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma | terminated | Phase 2 | 6 | Providence Health & ServicesOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04899492 | Evaluating Smoking Cessation Protocols in Cancer Patients: NRT, MI, CBT or Hypnotherapy(RESPIRE) | terminated | N/A | 21 | Institut Cancerologie de l'OuestOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT03991130 | High Dose IL-2 in Combination With Anti-PD-1 | terminated | Phase 2 | 6 | Gregory DanielsOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04221438 | Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement | terminated | Phase 2 | 3 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04527549 | Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma | terminated | Phase 2 | 5 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Aug 6, 2026 | clinicaltrials |
| NCT03412058 | Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists(CHECK'UP) | terminated | N/A | 152 | UNICANCEROTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT03178123 | The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery | terminated | Phase 2 | 6 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT03417739 | A Phase II Study of BVD-523 in Metastatic Uveal Melanoma | terminated | Phase 2 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 19 | NuCana plcOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT03114319 | Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 227 | Novartis PharmaceuticalsINDUSTRY | 9 | Jul 9, 2026 | clinicaltrials |
| NCT05571839 | A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 | 41 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 6 | Jul 1, 2026 | clinicaltrials |
| NCT04734704 | Defining the Role of the Skin Microbiome in Immune-related Adverse Events(SKINBIOTA) | terminated | N/A | 57 | University Hospital, BordeauxOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04702854 | Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma(BMUMM) | terminated | N/A | 1 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05130255 | GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 | terminated | Phase 1 | 23 | Y-mAbs TherapeuticsINDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT01272609 | Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel | terminated | Phase 3 | 25 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04695977 | CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma | terminated | Phase 2 / Phase 3 | 20 | Regeneron PharmaceuticalsINDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT02602756 | Study Assessing Two Models of Hypofractionated Protontherapy on Large Choroidal Melanomas(HYGROMEL) | terminated | N/A | 32 | Centre Antoine LacassagneOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04955743 | Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma | terminated | Phase 2 | 18 | Yale UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT03958383 | IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma | terminated | Phase 1 / Phase 2 | 8 | University of Wisconsin, MadisonOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06897735 | Exploratory Study of Inhaled Afatinib Dimaleate PK Profile(EDDIS-a1) | terminated | Phase 1 | 4 | Petrov, AndreyOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT04168528 | Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT | terminated | Phase 1 / Phase 2 | 13 | Universitair Ziekenhuis BrusselOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03645928 | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | terminated | Phase 2 | 225 | Iovance Biotherapeutics, Inc.INDUSTRY | 7 | May 15, 2026 | clinicaltrials |
| NCT06870487 | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers | terminated | Phase 1 | 6 | PfizerINDUSTRY | 2 | May 8, 2026 | clinicaltrials |
| NCT04902040 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | terminated | Phase 1 / Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT02562625 | Trial of Pembrolizumab and Radiotherapy in Melanoma(PERM) | terminated | Phase 2 | 17 | Royal Marsden NHS Foundation TrustOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05341349 | Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases | terminated | Phase 1 | 1 | Emory UniversityOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06974734 | A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies | terminated | Phase 1 | 8 | PfizerINDUSTRY | 2 | Apr 23, 2026 | clinicaltrials |
| NCT01604889 | A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 50 | Incyte CorporationINDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT03699995 | MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma | terminated | N/A | 17 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT02668770 | Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies | terminated | Phase 1 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 115 | SOTIO Biotech AGINDUSTRY | 4 | Mar 27, 2026 | clinicaltrials |
| NCT06580938 | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer | terminated | Phase 1 | 4 | PfizerINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT03420963 | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors | terminated | Phase 1 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04789668 | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | terminated | Phase 1 / Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06799533 | A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 | 11 | PfizerINDUSTRY | 5 | Mar 18, 2026 | clinicaltrials |
| NCT00421317 | Imatinib in Adult Patients With Metastatic Ocular Melanoma(O-Mel-Inib) | terminated | Phase 2 | 13 | Centre Oscar LambretOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT02439008 | Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response | terminated | N/A | 28 | Centre Oscar LambretOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05926960 | A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma(PORTSIDE) | terminated | Phase 2 | 38 | PfizerINDUSTRY | 5 | Mar 9, 2026 | clinicaltrials |
| NCT06287463 | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway | terminated | Phase 1 | 29 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Mar 5, 2026 | clinicaltrials |
| NCT03716193 | Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron Paramagnetic Resonance (EPR) Oximetry | terminated | N/A | 3 | West Virginia UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04093323 | Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma | terminated | Phase 2 | 1 | Roswell Park Cancer InstituteOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT03428581 | Preventing Lymphedema in Axillary Lymph Node Dissection | terminated | N/A | 264 | Mayo ClinicOTHER | 1 | Feb 24, 2026 | clinicaltrials |
Data updated 14 days agoSource updated Sep 16, 2026source: clinicaltrials